(a) End stage renal disease (ESRD) | |
---|---|

Adjusted for Confounders, Gender, and Systolic BP Hazard ratio, 95% CI, and P-value | |

Treatment with Ramipril (0 = no; 1 = yes) | P for interaction = 0.034 |

Phosphate strata [1 = I/II quartile; 2 = III quartile; 3 = IV quartile] | |

Treatment * phosphate strata | |

Albumin (1 g/dl) | 0.46 (0.27–0.77), P = 0.003 |

Hemoglobin (1 g/dl) | 0.89 (0.78–1.02), P = 0.10 |

Iohexol GFR (1 ml/min/1.73m^{2}) | 0.94 (0.92–0.96), P < 0.001 |

Urinary protein (1 g/24 h) | 1.13 (1.04–1.23), P = 0.003 |

Gender (0 = M; 1 = F) | 1.56 (0.85–2.85), P = 0.15 |

Systolic pressure (1 mmHg) | 1.03 (1.01–1.04), P < 0.001 |

(b) ESRD/doubling of serum creatinine | |
---|---|

Adjusted for confounders, gender and systolic BP Hazard ratio, 95% CI, and P-value | |

Treatment with Ramipril (0 = no; 1 = yes) | P for interaction = 0.021 |

Phosphate strata [1 = I/II quartile; 2 = III quartile; 3 = IV quartile] | |

Treatment * phosphate strata | |

Albumin (1 g/dl) | 0.53 (0.33–0.88), P = 0.01 |

Hemoglobin (1 g/dl) | 0.91 (0.80–1.04), P = 0.17 |

Iohexol GFR (1 ml/min/1.73m^{2}) | 0.95 (0.93–0.96), P < 0.001 |

Urinary protein (1 g/24 h) | 1.12 (1.04–1.21), P = 0.003 |

Gender (0 = M; 1 = F) | 1.34 (0.76–2.36), P = 0.23 |

Systolic pressure (1 mmHg) | 1.02 (1.01–1.04), P = 0.001 |

Data are expressed as hazard ratio, 95% CI, and

*P*-values.